1. Home
  2. VTGN vs IRD Comparison

VTGN vs IRD Comparison

Compare VTGN & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VTGN
  • IRD
  • Stock Information
  • Founded
  • VTGN 1998
  • IRD 2018
  • Country
  • VTGN United States
  • IRD United States
  • Employees
  • VTGN N/A
  • IRD N/A
  • Industry
  • VTGN Biotechnology: Pharmaceutical Preparations
  • IRD
  • Sector
  • VTGN Health Care
  • IRD
  • Exchange
  • VTGN Nasdaq
  • IRD NYSE
  • Market Cap
  • VTGN 59.8M
  • IRD 62.0M
  • IPO Year
  • VTGN N/A
  • IRD N/A
  • Fundamental
  • Price
  • VTGN $2.09
  • IRD $1.02
  • Analyst Decision
  • VTGN
  • IRD Strong Buy
  • Analyst Count
  • VTGN 0
  • IRD 3
  • Target Price
  • VTGN N/A
  • IRD $6.33
  • AVG Volume (30 Days)
  • VTGN 193.9K
  • IRD 803.8K
  • Earning Date
  • VTGN 08-12-2025
  • IRD 08-15-2025
  • Dividend Yield
  • VTGN N/A
  • IRD N/A
  • EPS Growth
  • VTGN N/A
  • IRD N/A
  • EPS
  • VTGN N/A
  • IRD N/A
  • Revenue
  • VTGN $486,000.00
  • IRD $13,651,000.00
  • Revenue This Year
  • VTGN N/A
  • IRD $51.41
  • Revenue Next Year
  • VTGN $943.32
  • IRD $68.84
  • P/E Ratio
  • VTGN N/A
  • IRD N/A
  • Revenue Growth
  • VTGN N/A
  • IRD N/A
  • 52 Week Low
  • VTGN $1.90
  • IRD $0.65
  • 52 Week High
  • VTGN $4.21
  • IRD $2.18
  • Technical
  • Relative Strength Index (RSI)
  • VTGN 39.11
  • IRD N/A
  • Support Level
  • VTGN $1.97
  • IRD N/A
  • Resistance Level
  • VTGN $2.07
  • IRD N/A
  • Average True Range (ATR)
  • VTGN 0.14
  • IRD 0.00
  • MACD
  • VTGN -0.01
  • IRD 0.00
  • Stochastic Oscillator
  • VTGN 12.00
  • IRD 0.00

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Share on Social Networks: